1.Evidence-informed tiering of non-invasive neuromodulation in mental disorders: from core conventional techniques to frontier exploration
Qiao WU ; Yan LUO ; Qiang ZHANG ; Hongyi SUN ; HuiMin LYU ; Menglei XIAO ; Zhong ZHENG
Sichuan Mental Health 2026;39(5):385-393
Pharmacotherapy and psychotherapy for mental disorders are hampered by suboptimal efficacy, high relapse rates, and limited applicability across patient populations, making neuromodulation as an important adjunctive treatment option. This evidence-oriented narrative review proposes a working tiering of mainstream non-invasive or minimally invasive neuromodulation techniques based on clinical maturity, systematically delineating their mechanistic underpinnings, clinical evidence profiles, and therapeutic positioning, while further outlining a patient-stratified clinical decision-making pathway. Current evidence indicates that modified electroconvulsive therapy (MECT) and standardized repetitive transcranial magnetic stimulation/intermittent theta-burst stimulation (rTMS/iTBS) constitute the core conventional techniques, with depressive disorder representing the most robustly supported indication. Magnetic seizure therapy (MST), as a promising optimized alternative to MECT, compared with MECT, MST shows a clear advantage in protecting autobiographical memory. Stanford neuromodulation therapy (SNT), an emerging rapid-acting protocol, may provide accelerated treatment options for treatment-resistant depression. Transcranial direct current stimulation (tDCS) has acquired a novel application paradigm following regulatory approval of certain home-use devices. Transcutaneous auricular vagus nerve stimulation (taVNS), external trigeminal nerve stimulation (eTNS), transcranial focused ultrasound (tFUS), and temporal interference stimulation (TIS) are still undergoing indication refinement and evidence accumulation. The central premise of this review is that clinical selection of non-invasive neuromodulation should not be predicated solely on efficacy rankings, but rather on a careful trade-off among evidence maturity, patient urgency, prior treatment history, symptom dimensions, accessibility, and individualization potential.

Result Analysis
Print
Save
E-mail